Research presented at an aging meeting in Boston found that overweight and diabetic people taking GLP-1 drugs have a biological age about two to three years younger than similar people on a placebo, according to Eli Lilly and Novo Nordisk, which make the drugs. GLP-1 agonists are already approved fo